Your browser doesn't support javascript.
loading
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
de Klerk, Leonie K; Patel, Anuj K; Derks, Sarah; Pectasides, Eirini; Augustin, Jeremy; Uduman, Mohamed; Raman, Nihal; Akarca, Fahire G; McCleary, Nadine J; Cleary, James M; Rubinson, Douglas A; Clark, Jeffrey W; Fitzpatrick, Bridget; Brais, Lauren K; Cavanaugh, Megan E; Rode, Amanda J; Jean, Melissa G; Lizotte, Patrick H; Nazzaro, Matthew J; Severgnini, Mariano; Zheng, Hui; Fuchs, Charles S; Enzinger, Peter C; Bass, Adam J.
  • de Klerk LK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Patel AK; Department of Medical Oncology, Amsterdam UMC - Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Derks S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Pectasides E; Department of Medical Oncology, Amsterdam UMC - Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Augustin J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Uduman M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Raman N; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Akarca FG; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • McCleary NJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Clark JW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Fitzpatrick B; Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Cavanaugh ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rode AJ; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Jean MG; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Lizotte PH; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Nazzaro MJ; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Severgnini M; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Zheng H; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Fuchs CS; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Enzinger PC; Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
  • Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA ab5147@cumc.columbia.edu peter_enzinger@dfci.harvard.edu.
J Immunother Cancer ; 9(9)2021 09.
Article en En | MEDLINE | ID: mdl-34593617
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article